# The Cochrane Verdict, and Who Funded the Evidence

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-19 | Updated: 2026-11-01

Canonical page: https://glpwatchdog.org/research/the-cochrane-verdict-and-who-funded-it

> Two WHO-funded Cochrane reviews find weight loss likely to be sustained; the semaglutide review calls it clinically relevant. Both also note the trials were paid for by the manufacturers: all of them, in tirzepatide's case.

## Key points

- Both reviews find weight loss likely to be sustained; the semaglutide review calls it clinically relevant and sustained while the drug is taken.
- The tirzepatide review: 'All the included studies were funded by the drug manufacturer.'
- Quality of life for tirzepatide: one study, interval running from 0.00 to 5.40.
- Effects on mortality and cardiovascular events remain limited or uncertain.

Cochrane, whose reviews grade how certain the evidence is for each outcome, has now reviewed semaglutide and tirzepatide for obesity, funded by the World Health Organization. Both reviews conclude the drugs produce weight loss that is likely to be sustained, and the semaglutide review calls that loss clinically relevant. Both also end on the same observation: **the evidence base was paid for by the companies selling the drugs.**[1][2]

## What they concluded about weight

Start with the positive finding, because it is the main one. Semaglutide produces a clinically relevant weight loss at medium-term follow-up compared with placebo, likely sustained in the long term *while taking the drug*.[1] Tirzepatide likewise produces weight loss at medium-term follow-up, likely sustained longer term.[2]

That is Cochrane language, and Cochrane does not hand out “clinically relevant” casually. On the question these drugs are prescribed for, the answer is yes.

## What they could not conclude

Everything else is where the certainty drains away, and the pattern is consistent across both reviews.

*Outcomes beyond weight, as graded by the Cochrane reviews. Note how much rests on single studies.*

| Outcome | Finding | Certainty |
| --- | --- | --- |
| Semaglutide — quality of life, major cardiovascular events, mortality | Effects likely limited or uncertain | Downgraded for risk of bias and imprecision |
| Tirzepatide — quality of life (SF-36 physical) | MD 2.70 (95% CI 0.00 to 5.40), 1 study, 1,032 participants | Low |
| Tirzepatide — mortality | RR 0.83 (95% CI 0.22 to 3.17), 1 study, 1,032 participants | Low |

> **Look at that quality-of-life interval.** It runs from 0.00 to 5.40, so its lower bound sits exactly on no difference at all, and it comes from a single trial. A drug that reliably removes a fifth of someone’s body weight has not yet been shown, at any decent level of certainty, to make them feel better. That gap between the scale and the person is where this field stands.

## The funding sentence

Both reviews say it, and Cochrane does not editorialize. For semaglutide: most studies were funded by the drug’s manufacturer, raising important concerns about conflicts of interest.[1] The tirzepatide review is blunter: all of the included studies were funded by the drug manufacturer.[2]

> Not most. All.

This is not an accusation that anyone falsified anything, and it should not be read as one. Industry funds most drug trials, because trials are expensive and regulators require them. But industry-funded trials systematically choose the questions, the comparators, the endpoints and the durations that suit the sponsor, and across medicine they report more favorable results than independent ones.[3] Both reviews call for independent studies, particularly in underrepresented populations.[1][2]

## What this changes for a reader

- **The weight claim is solid.** Two conservative reviews agree, and it is the claim these drugs are sold on.
- **Claims beyond weight deserve more skepticism than they usually get.** On quality of life and mortality the evidence is thin or graded low.
- **“While taking the drug” is doing real work** in the semaglutide conclusion. Our [maintenance trial article](https://glpwatchdog.org/research/tirzepatide-maintenance-dose-trial) covers what happens when people stop.
- **Independent evidence is coming.** The semaglutide review identified 46 ongoing studies that may strengthen future syntheses.

When a seller cites “the evidence” at you, remember that in the tirzepatide case it was entirely funded by the company that makes the drug. That does not make it wrong, but it is a reason to want more.

## Frequently asked questions

### What did Cochrane conclude about semaglutide and tirzepatide?

That both produce weight loss at medium-term follow-up that is likely to be sustained longer term. The semaglutide review calls that loss clinically relevant and adds that it holds while the drug is taken. Effects on other outcomes (quality of life, cardiovascular events and mortality) were graded as limited, uncertain or low certainty.

### Who funded the trials?

The manufacturers. Cochrane notes that most semaglutide studies were funded by the drug's manufacturer, raising important concerns about conflicts of interest, and that all included tirzepatide studies were manufacturer-funded. Both reviews call for independent research.

### Does that mean the results are wrong?

No, and it should not be read that way. Industry funds most drug trials because regulators require them and they are expensive. But sponsors shape which questions, comparators, endpoints and durations get studied, and industry-funded trials across medicine report more favorable results than independent ones.

### Do these drugs improve quality of life?

That has not been established at a useful level of certainty. For tirzepatide the estimate came from a single trial with a confidence interval running from 0.00 to 5.40, with its lower bound sitting exactly on no difference. For semaglutide, Cochrane described effects on quality of life as likely limited or uncertain.

### Is better evidence coming?

The semaglutide review identified 46 ongoing studies. Both reviews specifically call for further independent studies, particularly in underrepresented populations.

## References

1. Bracchiglione J, Meza N, Franco JV, et al. Semaglutide for adults living with obesity. Cochrane Database of Systematic Reviews. 2026. PMID: 41161683. https://pubmed.ncbi.nlm.nih.gov/41161683/
2. Franco JV, Guo Y, Varela LB, et al. Tirzepatide for adults living with obesity. Cochrane Database of Systematic Reviews. 2026. PMID: 41161687. https://pubmed.ncbi.nlm.nih.gov/41161687/
3. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews. 2017. PMID: 28207928. https://pubmed.ncbi.nlm.nih.gov/28207928/

---

Cite as: GLP Watchdog, Ruth Calder, "The Cochrane Verdict, and Who Funded the Evidence", published 2026-08-19, updated 2026-11-01. https://glpwatchdog.org/research/the-cochrane-verdict-and-who-funded-it

Canonical HTML page: https://glpwatchdog.org/research/the-cochrane-verdict-and-who-funded-it

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
